Stocks · Sun Pharma vs Cipla
Sun Pharma vs Cipla: which pharma stock is the better buy in 2026?
Specialty-led US scale versus a balanced India and respiratory franchise. A factual, signed comparison, informational and not a recommendation to buy or sell either stock.
The verdict
Sun Pharma is the larger pharma leader leaning on a specialty and US generics build-out, while Cipla is the more India and respiratory-weighted franchise with a steadier domestic base. Both are top Indian pharma names, so the call is specialty scale versus a balanced home-market mix. As of 2026-06-09, the systematic read scores Sun Pharmaceutical Industries Limited 49 and Cipla Limited 76 on the BazaarBaazi Crack Score, an Edge Score of 77 out of 100 to Cipla Limited.
BazaarBaaziSource & method
The matchup, at a glanceSUNPHARMA 49 · CIPLA 76
The Edge Score is a BazaarBaazi number for this matchup: 50 plus the gap between the two Crack Scores, capped at 100. 50 is a dead heat; the further above 50, the more decisively the systematic read favours the leader.
The case for eachStructural, not a tip
What each stock has going for it, factually. The Crack Score is the live systematic read; the edges are durable structural points, not forecasts.
The case for
Sun Pharmaceutical Industries Limited
Crack Score
49 / 100Mixed
Structural edges
- Largest Indian pharma company by scale and product breadth.
- A US specialty pipeline that aims to lift the mix above plain generics.
- Depth across chronic and acute therapies through a wide generic basket.
The case for
Cipla Limited
Crack Score
76 / 100Mixed
Structural edges
- A strong India-formulations brand and a leading respiratory and inhalation franchise.
- A disciplined US filing and complex-generics record.
- A steadier domestic base that softens US generic-pricing swings.
The live ratios, side by sideQ4 FY26 results · live spot
Valuation and quality ratios computed from each company's latest filed results times its live spot, the same engine as the fundamentals calculator. The price-derived ratios (P/E, P/B, yield) move with the market; the rest hold until the next results.
| Sun Pharmaceutical Industries Limited | Cipla Limited | |
|---|---|---|
| Return on equity | 13.8% | 11.3% |
| Net profit margin | 19.6% | 13.9% |
| EPS growth (YoY) | +4.9% | -26.4% |
| Debt to equity | 0.06 | 0.02 |
Stored from each company's filed results, as of 2026-06-09 and currency-checked; anything we could not verify is shown as n/a rather than guessed. Move the price and watch them react in the calculator.
The comparison, side by sideFactual
Sector, indicative market cap, the live Crack Score and stance, then the structural read on each business. The live valuation and quality ratios are in the table above; read any ratio against the sector and the company's own history.
| Sun Pharmaceutical Industries Limited | Cipla Limited | |
|---|---|---|
| Sector | Pharmaceuticals | Pharmaceuticals |
| Market capIndicative band, refreshed monthly. Read the live figure from the latest screen. | ~4.2 lakh cr | ~1.1 lakh cr |
| Crack Score | 49 / 100 | 76 / 100 |
| Systematic stance | Mixed | Mixed |
| What they do | India's largest pharma company by scale, a broad generics book plus a growing US specialty portfolio. | A top Indian pharma maker with a strong domestic-formulations and respiratory franchise plus US generics. |
| The moat | Scale, a specialty pipeline in the US and one of the deepest generic product baskets in the pack. | Brand strength in the India market, a respiratory and inhalation franchise and a disciplined US filing record. |
| Key driver 2026 to 2030 | Specialty-product ramp in the US, new launches and the pace of the generics cycle. | India-formulations growth, respiratory and complex generics, and US approvals. |
| Main risk | US pricing pressure, regulatory inspections and the pace of specialty adoption. | US generic price erosion, plant-inspection outcomes and competitive intensity at home. |
| Best suited to | The investor who wants the largest pharma name with US specialty optionality. | The investor who wants a more India-weighted, respiratory-led pharma franchise. |
Compute the live valuation and quality ratios for either stock, or read the full signed verdict on SUNPHARMA and CIPLA.
FAQ4 reader questions · AEO-eligible
The Sun Pharma vs Cipla call, distilled and schema-marked for AI Overview, Perplexity, and reader search.
Is Sun Pharma or Cipla a better stock to buy?
Sun Pharma is the larger, specialty and US-leaning leader, while Cipla is the more India and respiratory-weighted franchise with a steadier domestic base. Neither is a tip. Use the fundamentals calculator to compute each company's current P/E and ROE from the latest results before you decide.
Which pharma company has the bigger US business?
Sun Pharma runs the larger US presence, anchored by a growing specialty portfolio on top of generics, while Cipla's US book is more generics-led. Read the latest US revenue split from each company's results, the mix shifts as launches and approvals land.
Which is more dependent on the India market?
Cipla leans more on the domestic-formulations and respiratory franchise, which makes its India market share a bigger driver, while Sun Pharma's US specialty build adds an offshore growth vector. The two carry different geographic centres of gravity.
What is the biggest risk for these pharma stocks?
For both, US plant inspections and generic price erosion are the shared watch-items, since US regulatory and pricing outcomes move the stocks. Sun Pharma adds specialty-adoption risk and Cipla adds domestic-competition risk. The Crack Scores on this page show the current systematic read.
Other matchups
Hub
Compare stocks
All stock head-to-heads
Compare
TCS vs Infosys
Margin and scale versus the guidance-led growth read
Compare
HDFC Bank vs ICICI Bank
Post-merger liability franchise versus best-in-class return discipline
Compare
SBI vs HDFC Bank
Sovereign-backed scale and value versus private-sector return quality
Compare
Reliance vs Bharti Airtel
Diversified conglomerate optionality versus a focused premium-telecom compounder
Compare
HAL vs BEL
Platform-maker order book versus faster-converting defence electronics
Compare
Maruti vs Tata Motors
Mass-market distribution and margins versus JLR-led global cyclicality
Compare
ONGC vs Coal India
Oil-price-linked upstream versus a coal monopoly with a dividend floor
Compare
ICICI Bank vs PNB
Best-in-class private return profile versus a PSU asset-quality recovery
Compare
Trent vs Titan
Fast-fashion retail expansion versus a jewellery-led consumer compounder
Compare
Bajaj Finance vs Bajaj Finserv
The pure-play lending compounder versus the diversified financial-services holding
Compare
Adani Enterprises vs Adani Ports
The incubator conglomerate versus the cash-generating ports infrastructure operator
Compare
Tata Steel vs JSW Steel
An integrated global steelmaker versus a domestic-led capacity grower
Compare
NTPC vs Power Grid
Generation capacity growth versus regulated transmission stability
Compare
SBI vs ICICI Bank
Sovereign-backed scale and value versus best-in-class private return discipline
Compare
HUL vs Nestle India
Broad home and personal-care breadth versus a focused packaged-foods franchise